Results from our analysis were similar, except that in this analysis adalimumab also demonstrated superiority over placebo for clinical remission at end of induction; the results from Danese and colleagues [ 15 ] were close to significance.
← all excerpts
Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
1
—
—